Oral Semaglutide: Reduces Heart Failure & Cardiovascular Risk in Diabetes Patients

A new study suggests that oral semaglutide may reduce the risk of heart failure and major cardiovascular events, regardless of whether weight loss occurs. Semaglutide is the active ingredient in the obesity medication Wegovy and the diabetes medication Ozempic.

Significant Findings in a Large-Scale Trial

Researchers at Oregon Health & Science University analyzed data from a large clinical trial involving approximately 10,000 individuals with type 2 diabetes. The analysis revealed that oral semaglutide significantly lowered the risk of hospitalization and cardiovascular death due to heart failure. The findings were published in the JAMA Internal Medicine journal under the title ‘Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes.’

Study Design and Methodology

The study involved 9,650 adults with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) or chronic kidney disease. Participants were randomly assigned to receive either a daily dose of oral semaglutide or a placebo. The semaglutide dosage began at 3mg for the first four weeks, increased to 7mg for the subsequent four weeks, and then maintained at 14mg. Participants continued to receive their standard care throughout the study.

Did You Know? The average follow-up period for participants in the study was approximately four years.

Researchers assessed changes in blood sugar, weight, and blood pressure, alongside tracking instances of hospitalizations, emergency room visits, and cardiovascular or all-cause deaths.

Impact on Patients with and without Prior Heart Failure

Among patients who already had a history of heart failure at the study’s start, those taking oral semaglutide experienced a 22% reduction in the risk of hospitalization or death due to heart failure compared to the placebo group. This risk reduction was even more pronounced in patients with heart failure and preserved left ventricular ejection fraction. However, for patients without a prior heart failure diagnosis, there was little difference between the two groups.

the risk of major cardiovascular events – including heart attack, stroke, and cardiovascular death – was reduced by 14% with this effect consistent regardless of prior heart failure status.

Understanding the Mechanism

Researchers noted that heart failure is a common complication for individuals with type 2 diabetes. They also acknowledged that GLP-1 receptor agonist medications, like semaglutide, are known to reduce the risk of major cardiovascular events and death. However, the specific mechanisms by which oral semaglutide impacts heart health remain unclear.

Expert Insight: These findings suggest a potential benefit of oral semaglutide beyond glycemic control and weight management, offering a new dimension to consider when selecting treatment options for patients with type 2 diabetes and cardiovascular risk factors.

Experts suggest the drug may improve blood sugar, reduce inflammation, and potentially improve heart function, blood vessel health, and cholesterol levels through weight loss. Previous research has indicated that semaglutide injections can reduce the risk of heart attack or stroke by approximately 20%, independent of weight loss.

Future Implications and Availability

The research team concluded that, given the high prevalence of heart failure in patients with type 2 diabetes and obesity, these results provide clinicians with evidence to consider heart failure prevention when choosing treatments. Oral semaglutide may play a role in reducing heart failure events in patients with type 2 diabetes, ASCVD, chronic kidney disease, and heart failure.

Currently, oral semaglutide is available in select areas of the United States and is expected to be launched in other countries, including the United Kingdom, in the near future.

Frequently Asked Questions

Q1. For which patients was oral semaglutide effective?

Oral semaglutide demonstrated significant reductions in the risk of hospitalization and cardiovascular death related to heart failure in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) or chronic kidney disease, particularly those with a pre-existing heart failure diagnosis.

Q2. Does oral semaglutide help heart health even without weight loss?

Yes. The study showed that the risk of heart failure and major cardiovascular events decreased regardless of weight loss, potentially due to improvements in blood sugar control and reduced inflammation.

Q3. Were the effects consistent across all participants?

No. Patients without a prior heart failure diagnosis showed little difference in heart failure risk between the oral semaglutide and placebo groups.

As oral semaglutide becomes more widely available, how might these findings influence conversations between patients and their doctors regarding cardiovascular health management?